Investors

Immunovaccine

IMV Inc. is a clinical-stage immuno-oncology company dedicated to making immunotherapies more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV's proprietary drug development platform provides a patented delivery formulation that enables controlled and prolonged exposure of antigens to the immune system. Lead product candidate DPX-Survivac is currently being evaluated in several clinical trials in advanced ovarian cancer in combination with other innovative immunotherapy agents.

© 2018 IMV Inc. All rights reserved.

130 Eileen Stubbs Avenue,
Suite 19
Dartmouth, Nova Scotia B3B 2C4

Québec Office 
2875 Boulevard Laurier 
Delta 1, Suite 220 
Québec, Québec, Canada 
G1V 2M2 
Tel: +1 581.741.0519